Table 3.

Results of univariable and multivariable analyses for predictors of sVT/SCD in active CS

	Univariable			Multivariable
				Model 1			Model 2
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Age	1.064	1.006 to 1.125	0.030	1.071	0.977 to 1.174	0.145
Male	2.467	0.881 to 6.907	0.087	4.020	0.796 to 20.290	0.092
NYHA class	3.172	0.894 to 11.258	0.082	0.604	0.111 to 3.275	0.559
LVDd, mm	1.038	0.983 to 1.095	0.180	0.947	0.835 to 1.073	0.392
LVEF, %	0.977	0.937 to 1.019	0.281
RWMA score	1.693	0.848 to 3.382	0.117	0.599	0.186 to 1.928	0.390
SBP, mm Hg	0.957	0.920 to 0.996	0.032	0.938	0.872 to 1.010	0.089
BNP, pg/mL	1.005	1.002 to 1.009	0.005	1.005	0.997 to 1.012	0.246
CRP, mg/dL	0.019	0.000 to 19.801	0.264
eGFR, mL/min/1.73 m2	0.994	0.970 to 1.018	0.611
U-8-OHdG, ng/mg･Cr	1.124	1.054 to 1.199	<0.001	1.097	0.975 to 1.234	0.124	1.118	1.046 to 1.195	0.001
Presence of VA	4.687	1.654 to 13.285	0.004	5.096	1.005 to 25.849	0.049	4.180	1.380 to 12.664	0.011
History of sVT	3.940	1.426 to 10.883	0.008	2.323	0.493 to 10.942	0.287	2.728	0.904 to 8.234	0.075
Inducibility on VT study (missing 45/61)	0.495	0.110 to 2.233	0.360
Amiodarone	2.133	0.772 to 5.893	0.144	0.880	0.134 to 5.777	0.894
Beta-blocker	1.426	0.402 to 5.059	0.583
Loop diuretic	2.887	1.023 to 8.143	0.045	0.499	0.081 to 3.094	0.455
Steroid	2.201	0.496 to 9.765	0.299
Device (PM/ICD/CRT)	3.298	0.739 to 14.705	0.118	1.934	0.241 to 15.533	0.0.535

BNP, brain natriuretic peptide; CRP, C reactive protein; CRT, cardiac resynchronisation therapy; CS, cardiac sarcoidosis; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator; LVDd, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PM, pacemaker; RWMA, regional wall motion abnormality; SBP, systolic blood pressure; SCD, sudden cardiac death; sVT, sustained ventricular tachycardia; U-8-OHdG, urinary 8-hydroxy-2′-deoxyguanosine; VA, ventricular aneurysm; VT, ventricular tachycardia.